- Posted June 28, 2013
- Tweet This | Share on Facebook
Esperion Therapeutics shares jump in trading debut
NEW YORK (AP) -- Shares of Esperion Therapeutics Inc. jumped Wednesday in their first day of trading after the drug developer raised $70 million in an initial public offering.
In midday trading, the drug developer's shares rose $1.27, or 9 percent, to $15.27, after jumping as high as $17.40 earlier in the session. Earlier, Esperion sold 5 million shares for $14 each, resulting in $70 million in proceeds.
Esperion is developing a new kind of experimental drug that would lower LDL cholesterol, commonly known as "bad" cholesterol. Roger Newton, the company's founder, executive chairman and chief scientific officer, is a co-discoverer of the cholesterol drug Lipitor, the world's top-selling drug for more than a decade.
The shares are trading on the Nasdaq under the ticker symbol "ESPR." The company is based in Plymouth, Mich.
Published: Fri, Jun 28, 2013
headlines Oakland County
- Associations gather for Spring Fling
- Supreme Court denies rehearing request by attorneys sanctioned for meritless election lawsuit
- Law school conducts ‘Know Your Rights Day’ for high school students
- Oakland County household hazardous waste dropoff events promote environmental stewardship and safeguard communities
- Nessel testifies in support of BRITE Act
headlines National
- Incarceration series includes female inmates but doesn’t tell full story
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- Former DOJ official who alleged election fraud violated at least one ethics rule, ethics committee says
- Winston & Strawn will provide reduced-cost legal services for routine tasks under Winston Legal Solutions umbrella
- Should Justice Sotomayor retire? Chemerinsky, White House haven’t joined calls for her to step down
- Which BigLaw firms are increasing lateral associate hiring the most? One made legal headlines last year